Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

[Mucopenetrating nanoparticles: vehicles for the oral administration of paclitaxel].

Zabaleta V, Calleja P, Espuelas S, Corrales L, Pío R, Agüeros M, Irache JM.

Ann Pharm Fr. 2013 Mar;71(2):109-18. doi: 10.1016/j.pharma.2012.12.005. Epub 2013 Feb 27. French.

PMID:
23537412
2.

Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study.

Zabaleta V, Ponchel G, Salman H, Agüeros M, Vauthier C, Irache JM.

Eur J Pharm Biopharm. 2012 Aug;81(3):514-23. doi: 10.1016/j.ejpb.2012.04.001. Epub 2012 Apr 10.

PMID:
22516136
3.

Controlled Release, Intestinal Transport, and Oral Bioavailablity of Paclitaxel Can be Considerably Increased Using Suitably Tailored Pegylated Poly(Anhydride) Nanoparticles.

Calleja P, Espuelas S, Vauthier C, Ponchel G, Irache JM.

J Pharm Sci. 2015 Sep;104(9):2877-86. doi: 10.1002/jps.24354. Epub 2015 Jan 19.

PMID:
25600579
4.

Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation.

Xin H, Chen L, Gu J, Ren X, Wei Z, Luo J, Chen Y, Jiang X, Sha X, Fang X.

Int J Pharm. 2010 Dec 15;402(1-2):238-47. doi: 10.1016/j.ijpharm.2010.10.005. Epub 2010 Oct 8.

PMID:
20934500
5.

Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.

Zhan C, Gu B, Xie C, Li J, Liu Y, Lu W.

J Control Release. 2010 Apr 2;143(1):136-42. doi: 10.1016/j.jconrel.2009.12.020. Epub 2010 Jan 7.

PMID:
20056123
6.

Stabilized micelles as delivery vehicles for paclitaxel.

Yoncheva K, Calleja P, Agüeros M, Petrov P, Miladinova I, Tsvetanov C, Irache JM.

Int J Pharm. 2012 Oct 15;436(1-2):258-64. doi: 10.1016/j.ijpharm.2012.06.030. Epub 2012 Jun 18.

PMID:
22721848
7.

Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy.

Ruttala HB, Ko YT.

Pharm Res. 2015 Mar;32(3):1002-16. doi: 10.1007/s11095-014-1512-2. Epub 2014 Sep 12.

PMID:
25213777
8.

Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration.

Li R, Eun JS, Lee MK.

Arch Pharm Res. 2011 Feb;34(2):331-7. doi: 10.1007/s12272-011-0220-2. Epub 2011 Mar 6.

PMID:
21380818
9.

Cytotoxicity of Paclitaxel in biodegradable self-assembled core-shell poly(lactide-co-glycolide ethylene oxide fumarate) nanoparticles.

He X, Ma J, Mercado AE, Xu W, Jabbari E.

Pharm Res. 2008 Jul;25(7):1552-62. doi: 10.1007/s11095-007-9513-z. Epub 2008 Jan 15.

PMID:
18196205
10.

Pharmacokinetics and antitumor efficacy of paclitaxel-cyclodextrin complexes loaded in mucus-penetrating nanoparticles for oral administration.

Calleja P, Espuelas S, Corrales L, Pio R, Irache JM.

Nanomedicine (Lond). 2014 Jul;9(14):2109-21. doi: 10.2217/nnm.13.199. Epub 2014 Jan 28.

PMID:
24471503
11.

Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration.

Lv PP, Wei W, Yue H, Yang TY, Wang LY, Ma GH.

Biomacromolecules. 2011 Dec 12;12(12):4230-9. doi: 10.1021/bm2010774. Epub 2011 Nov 10.

PMID:
22044456
12.

Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol).

Wu L, Tang C, Yin C.

Drug Dev Ind Pharm. 2010 Apr;36(4):439-48. doi: 10.3109/03639040903244472.

PMID:
19824865
14.

Cytoreductive surgery and intraoperative administration of paclitaxel-loaded expansile nanoparticles delay tumor recurrence in ovarian carcinoma.

Gilmore D, Schulz M, Liu R, Zubris KA, Padera RF, Catalano PJ, Grinstaff MW, Colson YL.

Ann Surg Oncol. 2013 May;20(5):1684-93. doi: 10.1245/s10434-012-2696-5. Epub 2012 Nov 6.

PMID:
23128939
15.

Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.

Danhier F, Magotteaux N, Ucakar B, Lecouturier N, Brewster M, Préat V.

Eur J Pharm Biopharm. 2009 Oct;73(2):230-8. doi: 10.1016/j.ejpb.2009.06.015. Epub 2009 Jul 3.

PMID:
19577643
16.

Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.

Park JH, Park JH, Hur HJ, Woo JS, Lee HJ.

Eur J Pharm Sci. 2012 Feb 14;45(3):296-301. doi: 10.1016/j.ejps.2011.11.021. Epub 2011 Dec 8.

PMID:
22172604
17.

Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation.

Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD.

Int J Pharm. 2007 Jun 29;338(1-2):317-26. Epub 2007 Feb 13.

PMID:
17368984
18.

PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation.

Jiang X, Xin H, Sha X, Gu J, Jiang Y, Law K, Chen Y, Chen L, Wang X, Fang X.

Int J Pharm. 2011 Nov 28;420(2):385-94. doi: 10.1016/j.ijpharm.2011.08.052. Epub 2011 Sep 6.

PMID:
21920419
19.

Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles.

Agüeros M, Zabaleta V, Espuelas S, Campanero MA, Irache JM.

J Control Release. 2010 Jul 1;145(1):2-8. doi: 10.1016/j.jconrel.2010.03.012. Epub 2010 Mar 27.

PMID:
20347897
20.

Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy.

Mugabe C, Hadaschik BA, Kainthan RK, Brooks DE, So AI, Gleave ME, Burt HM.

BJU Int. 2009 Apr;103(7):978-86. doi: 10.1111/j.1464-410X.2008.08132.x. Epub 2008 Oct 31.

Supplemental Content

Support Center